Giant Biogene Holding Co. Ltd.

As of December 31, 2025, Giant Biogene Holding Co. Ltd. carries a market capitalization of 35.07B, placing it among publicly traded companies globally. Its enterprise value stands at 25.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Giant Biogene Holding Co. Ltd.'s next confirmed earnings release is scheduled for March 29, 2027.

As of December 31, 2025, Giant Biogene Holding Co. Ltd. has 1.05B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Giant Biogene Holding Co. Ltd. maintains a current ratio of 11.27, meaning it holds 11.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, Giant Biogene Holding Co. Ltd.'s stock has declined approximately 45.68% over the past 52 weeks. The 50-day moving average sits at 25.31, while the 200-day moving average is 28.96.

As of December 31, 2025, Giant Biogene Holding Co. Ltd. holds 9.23B in cash and equivalents against 10.78M in total debt, resulting in a net debt position of -7.02B. Total book value stands at 11.03B, with working capital of 9.15B providing operational flexibility.